BioSpace News Archive

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced Christine Arme as their Chief Commercial Officer.

JW Therapeutics Co. Ltd, an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the preliminary clinical data on relmacabtagene autoleucel injection in adults with active systemic lupus erythematosus in China at the 2024 European Alliance of Associations for Rheumatology Congress.

Aktieinvest FK AB will subscribe for all 1,700,000 shares of series C at a subscription price of SEK 0.5 per share, equal to the quota value of the shares.

Attralus, Inc. announced 11 data presentations, including two oral presentations related to the use of 124I-evuzamitide, the company’s pan-amyloid binding imaging agent in development for the diagnosis of cardiac amyloidosis.

PMV Pharmaceuticals, Inc today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences in June.

Omega Therapeutics, Inc. today announced that management will participate in fireside chats at two upcoming investor conferences.

LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the first quarter of fiscal year 2024 ended on March 31, 2024.

LAVA Therapeutics N.V. today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference.

Monte Rosa Therapeutics, Inc. today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer.

Celcuity Inc. announced that it plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant.